Global Manufacturing Footprint Bora Pharmaceuticals operates ten state-of-the-art CGMP manufacturing facilities across Asia and North America, enabling flexible global production and rapid market access for biopharma partners.

Strategic Acquisitions Recent acquisitions, including Upsher-Smith Laboratories and Emergent BioSolutions assets, demonstrate Bora’s expansion strategy into generic drugs and specialized manufacturing, presenting opportunities for supply chain partnerships and joint ventures.

Diverse Product Capabilities Specializing in complex oral solids, liquids, biologics, and sterile injectables, Bora offers end-to-end development from early phase to commercial production, making it a comprehensive partner for drug development projects.

Strong Market Position With revenues estimated between 250 million to 500 million USD and a growing presence in North America and Asia, Bora is well-positioned to serve multinational biopharma companies seeking reliable manufacturing collaborations.

Leadership & Innovation Hiring key executives like a Chief Commercial Officer and maintaining high standards in R&D and analytical testing suggest Bora’s focus on operational excellence and innovative manufacturing solutions suitable for expanding client needs.